msi-h
Entity, reached from Hormuz.
- Evidence
- 80 documents · 34 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 11 Mar 2026, last seen 10 Oct 2026
- Measured
- 11% of mentions say something specific about it; the rest only name it
- As of
- 10 Oct 2026
Where this comes from
- Annals of Oncology · 2026-09-13 · Corrigendum to “925MO First-in-human phase I/Ib study of the oral Werner (WRN) helicase inhibitor HRO761 in patients (pts) with microsatellite instability-high (MSI-… (opens the source in a new tab)
- crc-digest · 2026-09-09 · Cytokines May Modulate Checkpoint Inhibitor Response in MSI-H CRC (opens the source in a new tab)
- crc-digest · 2026-09-09 · Cost-Effectiveness Analysis Compares Immunotherapy Options for MSI-H/dMMR mCRC (opens the source in a new tab)
- Clin Case Rep · 2026-09-09 · A Lynch Syndrome Family With Germline MLH1 c.931A>G Showing Preserved Tumor MMR Immunostaining but MSI-H Status: A Case Report. (opens the source in a new tab)
- crc-digest · 2026-09-03 · Patients With Poor Performance Status Still Benefit From Immunotherapy in MSI-H CRC (opens the source in a new tab)
- Front Cell Infect Microbiol · 2026-09-03 · Gut microbiome-mediated primary and acquired resistance to immune checkpoint inhibitors in MSI-H/dMMR colorectal cancer: mechanisms, biomarkers, and therape… (opens the source in a new tab)
- crc-digest · 2026-09-02 · Single-cell study identifies ETV4-MC1R pathway driving immunotherapy resistance in MSI-H CRC (opens the source in a new tab)
- ESMO Gastrointest Oncol · 2026-09-01 · Prognostic relevance of secondary actionable fusions in MLH1-deficient dMMR/MSI-H gastrointestinal tumors treated with pembrolizumab. (opens the source in a new tab)
- crc-digest · 2026-08-25 · Dual checkpoint blockade compared to single-agent PD-1 in MSI-H metastatic colorectal cancer (opens the source in a new tab)
- MSI-H · 2026-08-23 · Immunotherapy (MSI-H) (opens the source in a new tab)
2 more on file, counted in the evidence above.
What is claimed about it
Situations it is named in
Who it moves with
- co-mentioned with colorectal cancer (68 documents)seen together
- co-mentioned with immunotherapy (60 documents)seen together
- co-mentioned with braf (11 documents)seen together
- co-mentioned with t-cell (8 documents)seen together
- co-mentioned with china (8 documents)seen together